Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Minnetronix
The PILLAR-XT study is designed to further confirm safety and characterize efficacy of Neurapheresis therapy. The study works in tandem with the current SOC treatments for SAH and does not detract from the established care pathways, or deny enrolled subjects proven therapies. The PILLAR-XT study utilizes the established skill sets of chosen Investigators who are already trained in the treatment and care of SAH patients and insertion/management of lumbar drains.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Modified Fisher Grade 2, 3 or 4
Hunt \& Hess I-IV
First aneurysmal SAH
Patient is ≤ 48 hours post bleeding event
World Federation of Neurosurgeons (WFNS) Grades I-IV
You may not be if
Pregnancy
Patients with a SAH due to mycotic aneurysm or AV malformation
Patients who present with an acute MI or unstable angina
Imaging demonstrates supratentorial mass lesions \> or = 15 cc
Imaging demonstrates \> or = 2 mm of mid-line-shift associated with infarction and or edema
Effacement of the basilar cisterns
Vasospasm on admission as defined by angiographic evidence
Patients with a coagulopathy that cannot be reversed
Thrombocytopenia def. platelet count \< 100,000
Patients on low molecular weight heparin such as Lovenox
Non-communicating Obstructive hydrocephalus
Existing hardware that prevents accurate CT imaging
Pre-existing Lumbar Drain
Local skin infections or eruptions over the puncture site
Signs of CNS systemic infection, sepsis or pneumonia
